Under the agreement Proteros initially will provide high quality crystallography services on certain projects to support HMP’s drug discovery projects. HMP is focused on the areas of oncology and autoimmune diseases. Proteros will support HMP’s discovery research with Protein-Ligand-structure analysis throughout 2011 and beyond with selected compounds from HMP. This collaboration will significantly accelerate HMP’s drug discovery process, particularly in medicinal chemistry.
Cony D’Cruz, Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be selected by Hutchison MediPharma to work with it on its multitude of exciting targets and we believe that our in-depth structural biology expertise is particularly suited to accelerate its efforts in its target areas.”